Abstract
ObjectivePrevious studies have suggested a correlation between glucose transporter-1 (GLUT-1) expression and survival outcomes in pancreatic cancer, although the results were inconsistent. We subsequently carried out a meta-analysis, with the aim of comprehensively reevaluating the associations between GLUT-1 expression and overall survival (OS) and other clinical features of pancreatic cancer.ResultsEight studies, with a total of 538 cases, were included in the final meta-analysis. The HR and 95% CI for OS were 1.79 and 1.19-2.7, respectively (p=0.005). GLUT-1 overexpression was associated with tumor size (>2 cm vs. ≤2 cm; OR=2.16, 95% CI=1.2-3.9, p=0.01) and lymph node metastasis (yes vs. no; OR=3.29, 95% CI=1.38-7.84, p=0.007). However, there was no significant association between GLUT-1 expression and histological grade, age, sex, TNM stage, or vascular invasion status. There was no evidence of significant publication bias in this meta-analysis.Materials and MethodsRelevant databases were searched using predefined searching items until September 2016. The pooled hazard ratios (HR) with 95% confidence interval (CI) for OS and the pooled odds ratio (OR) with 95% CI for clinical factors were calculated.ConclusionsHigh GLUT-1 expression predicted shorter OS in patients with pancreatic cancer. Moreover, GLUT-1 expression was associated with a tumor size of >2 cm and presence of lymph node metastasis.
Highlights
Pancreatic cancer has a high mortality rate among all cancer types [1]
The hazard ratios (HR) and 95% confidence interval (CI) for overall survival (OS) were 1.79 and 1.19-2.7, respectively (p=0.005)
glucose transporter-1 (GLUT-1) overexpression was associated with tumor size (>2 cm vs. ≤2 cm; odds ratio (OR)=2.16, 95% CI=1.2-3.9, p=0.01) and lymph node metastasis
Summary
Pancreatic cancer has a high mortality rate among all cancer types [1]. Of the 10 leading types of cancer in the United States, pancreatic cancer has a morbidity of approximately 3%, while the total mortality due to pancreatic cancer is approximately 7%[2]. The 5-year survival rate of patients with pancreatic cancer is 6%, and only one-fifth of all patients are eligible for curative surgery at the time of first diagnosis [3]. Carbohydrate antigen 19-9 are independent prognostic factors that are often used www.impactjournals.com/oncotarget to predict survival; these biomarkers lack sensitivity or specificity for prognostication [5]. In order to be able to make more individualized therapeutic regimens for patients, it is important to identify novel and valid biomarkers for pancreatic cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
